Drug intelligence / Profile preview

Faringesic

Development stage: Unknown
Lead developer: Diafarm
Modality: Small Molecules
Administration: Oral

Overview

Faringesic is an over-the-counter (OTC) combination throat lozenge developed by Diafarm (a subsidiary of Faes Farma). It contains chlorhexidine dihydrochloride, a biguanide antiseptic with broad-spectrum antimicrobial activity, and benzocaine, an ester-type local anesthetic. The product is indicated for the symptomatic relief of mild mouth and throat infections, including throat irritation, hoarseness, and small mouth ulcers (aphthous ulcers), in adults and children over six years of age. It is available in various flavors such as lemon, mint, and orange.

Brand names: Faringesic

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Faringesic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Faringesic.

Explore the full profile